KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2024 value amounting to $1.4 million.

  • Halozyme Therapeutics' Treasury Shares rose 2277.12% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year increase of 2277.12%. This contributed to the annual value of $1.4 million for FY2024, which is 2277.12% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Treasury Shares of $1.4 million as of Q4 2024, which was up 2277.12% from $19.1 million recorded in Q2 2024.
  • In the past 5 years, Halozyme Therapeutics' Treasury Shares ranged from a high of $19.1 million in Q2 2024 and a low of $88307.0 during Q2 2020
  • For the 5-year period, Halozyme Therapeutics' Treasury Shares averaged around $4.8 million, with its median value being $3.9 million (2021).
  • In the last 5 years, Halozyme Therapeutics' Treasury Shares skyrocketed by 107493.18% in 2021 and then tumbled by 7468.14% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Treasury Shares stood at $6.5 million in 2020, then tumbled by 40.0% to $3.9 million in 2021, then grew by 15.38% to $4.5 million in 2022, then crashed by 74.68% to $1.1 million in 2023, then increased by 22.77% to $1.4 million in 2024.
  • Its last three reported values are $1.4 million in Q4 2024, $19.1 million for Q2 2024, and $12.6 million during Q1 2024.